I n healthy conditions, nitric oxide (NO) acts as a modulator of both vascular tone and structure, playing a predominant protective role on the vasculature. In genetic hypertension, a number of endothelium-derived contracting factors have been identified. These include several prostanoids, such as prostaglandins and thromboxane A 2 , derived from arachidonic acid by the enzyme cyclooxygenase (COX), and reactive oxygen species (ROS), 1,2 generated by several enzymatic sources, including nicotinamide adenine dinucleotide phosphate (NAD[P]H) oxidase, xanthine oxidase (XO), uncoupled NO synthase (NOS), or COXs itself.
human hypertension. However, 2 different isoforms of COX are known to exist. 9 In most tissues, COX-1 is constitutively expressed to produce physiological prostanoids, whereas COX-2 is often induced by a number of stimuli, including inflammation or growth factors. 10 Nevertheless, COX-2 is also expressed constitutively in several organs. In particular, within the vasculature, endothelial and vascular smooth muscle cells do express both isoforms, with COX-1 being usually expressed at a higher extent than COX-2. 10 Which of these 2 COX isoenzymes is the predominant isoform contributing to ROS generation in EH remains still undetermined. Therefore, the primary aim of this study was to assess the role of COX-1 and COX-2 as determinants of endothelial dysfunction in small resistance arteries from EH, as well as their cross-talks with NO and ROS. Second, we investigated whether other pathways, including NAD(P)H oxidase, uncoupled NOS, or XO, may participate as adjunctive sources of ROS in small resistance arteries.
Methods
Detailed methods are available in the online-only Data Supplement.
Study Population
The main study included 14 mild-moderate EH and 14 matched normotensive control subjects (NT). An adjunctive group of 7 matched EH was further assessed for control experiments (Table) . The protocol was approved by the local ethical committee, and the informed consent was obtained from each participant.
Preparation of Small Arteries and Functional Experiments
All participants underwent a biopsy of subcutaneous fat from the anterior abdominal region, taken during the surgical procedure. Small arteries were isolated and mounted in a pressurized myograph, as previously described. 11, 12 Endothelium-dependent and endothelium-independent relaxations were assessed by cumulative concentrations of acetylcholine (ACh, 0.001-100 μmol/L) and sodium nitroprusside (0.01-100 μmol/L) in vessels precontracted with norepinephrine (1 μmol/L).
Figure 1.
Relaxations to acetylcholine±NG-nitro-l-arginine methyl ester (L-NAME), ascorbic acid (Asc. Acid), or both in normotensive control subjects (A) and essential hypertensive patients (B). Data as mean±SEM (n=8 each). *P<0.001. Figure 2 . A, Relaxations to acetylcholine±NG-nitro-larginine methyl ester (L-NAME), DuP-697, or both in essential hypertensive patients. B, Relaxations to acetylcholine±L-NAME, apocynin (Apo), or Apo+DuP-697+L-NAME in essential hypertensive patients. Data as mean±SEM (n=8 each). *P<0.001; †P<0.05. 
Influence of NO Availability and ROS Production on Endothelium-Dependent Relaxation
To evaluate NO availability and ROS production, curves to ACh were constructed before and after 30-minute incubation with the NOS inhibitor NG-nitro-l-arginine methyl ester (L-NAME; 100 μmol/L; Sigma), the antioxidant ascorbic acid (100 μmol/L; Sigma), or both.
Influence of COX-1, COX-2 Activity, and Thromboxane-Prostanoid Receptors
Furthermore, in small arteries of EH and NT, the roles of COX-1 and COX-2 on NO availability were assessed by repeating ACh after 30-minute incubation with SC-560 (1 µmol/L, selective COX-1 inhibitor), DuP-697 (1 µmol/L, selective COX-2 inhibitor), and simultaneously L-NAME+SC-560, or DuP-697. In adjunctive vessels of EH (n=7), the roles of COX-1 and COX-2 were assessed by repeating ACh after 30-minute incubation with indomethacin (10 µmol/L, nonselective COX inhibitor; Sigma) or SC-560+DuP-697. The contribution of thromboxane-prostanoid (TP) receptors was tested by repeating ACh after incubation with the TP receptor antagonist SQ-29548 (1 mmol/L; Cayman Chemical).
Influence of NAD(P)H Oxidase, Uncoupled NOS, and XO
In vessels of EH, ACh was repeated after 30-minute incubation with apocynin (10 μmol/L; Sigma) and diphenylene iodinium (DPI, 10 μmol/L; Sigma), the 2 different NAD(P)H oxidase inhibitors; sepiapterin, a precursor of tetrahydrobiopterin which is a cofactor for NO synthesis (100 μmol/L; Sigma); or allopurinol, the XO inhibitor (100 μmol/L; Sigma).
13,14

Detection of Vascular Superoxide Anion Generation
The in situ production of superoxide anion was measured by means of the fluorescent dye dihydroethidium (Sigma), as previously described. 12 Each segment was analyzed simultaneously after incubation with ascorbic acid (100 μmol/L), DuP-697 (100 μmol/L), SC-560 (100 µmol/L), apocynin (100 μmol/L), DPI (100 μmol/L), allopurinol (100 μmol/L), sepiapterin (100 μmol/L), or Krebs solution.
Western Blot Analysis of COX-1 and COX-2
Western blot analysis was carried out to detect COX-1 and COX-2 protein expression in small arteries of EH and NT.
Immunostaining of COX Isoforms
Immunohistochemical analysis of COX-1 and COX-2 in small vessels from EH and NT was detected, as previously described.
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Data Analysis
Results are presented as mean±SEM and analyzed by repeated measures ANOVA, followed by 
Results
The baseline clinical characteristics of all participants are summarized in the Table. Baseline and NE-induced contraction of vascular lumen diameters did not significantly differ among groups (Table) .
Role of NO Availability and ROS Production on Endothelium-Dependent Relaxation
Small arteries of EH showed significantly (P<0.001) impaired relaxation to ACh compared with NT ( Figure 1A and 1B; Figure S1A ), whereas responses to sodium nitroprusside were similar in EH and NT ( Figure S1B ). In arteries of NT, the relaxation to ACh was significantly blunted by L-NAME (100 μmol/L; Figures 1A and 3) and not affected by ascorbic acid (100 μmol/L; Figure 1A ). By contrast, in vessels of EH, the relaxation to ACh was resistant to L-NAME ( Figures 1B and 3 ). In these vessels, ascorbic acid normalized the endothelium-dependent relaxation and restored the inhibitory effect of L-NAME on ACh (Figures 1B and 3; Figure S1A ).
Influence of COX-1, COX-2 Activity, and TP Receptors on Endothelium-Dependent Relaxation
In arteries of NT, relaxation to ACh (91.4±2.1%) was not modified by SC-560 (1 μmol/L; 92.3±2.4%) or DuP-697 (1 μmol/L; 92.9±2.7%). By contrast, in vessels of EH, response to ACh (58.2±2.1%), while not modified by SC-560 (59.1±2.6%), was significantly potentiated, but not completely normalized, by DuP-697 (Figure 2A ), which also improved the inhibitory effect of L-NAME on ACh (Figures 2A and 3 ).
In vessels from EH, indomethacin (10 μmol/L) improved the relaxing response to ACh to a similar extent than DuP-697 ( Figure S2 ). No further improvement of relaxation to ACh emerged when DuP-697 and SC-560 were simultaneously incubated when compared with DuP-697 alone ( Figure S2 ). SQ-29548 (1 mmol/L) failed to affect the relaxation to ACh ( Figure S2 ).
Involvement of NAD(P)H Oxidase, Uncoupled NOS, and XO
In EH, apocynin (10 μmol/L) moderately, but significantly, improved the relaxation to ACh ( Figure 2B ) and partly enhanced the inhibition by L-NAME on ACh ( Figures 2B and 3) . Simultaneous apocynin and DuP-697 infusion normalized the relaxation to ACh ( Figure 2B ; Figure S1A ) and restored the inhibition of L-NAME on ACh ( Figures 2B and 3) . Similarly, DPI (10 μmol/L) enhanced the relaxation to ACh and, in part, restored the inhibitory effect of L-NAME on ACh ( Figure S3 ). Relaxation to ACh (59.5±1.4%) was unmodified by sepiapterin (100 μmol/L; 59.1±2.5%) or allopurinol (100 μmol/L; 60.3±2.7%).
Analysis of Vascular Superoxide Anion Generation
Dihydroethidium analysis revealed a dramatic increase in superoxide anion production in vessels from EH ( Figure 4 ). The superoxide excess was strongly reduced by DuP-697. Apocynin and DPI moderately, but significantly, decreased superoxide generation, whereas SC-560, sepiapterin, or allopurinol was devoid of any effect ( Figure 4 ). Superoxide production was almost abrogated on incubation with ascorbic acid (Figure 4 ).
Western Blot Analysis of COX-1 and COX-2
Small vessels of NT expressed both COX-1 and COX-2 isoforms, but the level of COX-1 expression was higher compared with COX-2 ( Figure 5 ). In small vessels from EH, the COX-1 protein was expressed at a similar extent as in controls. By contrast, a significantly higher expression of COX-2 was detected in arteries of EH compared with that of NT ( Figure 5 ).
Immunohistochemical Analysis of COX-1 and COX-2
Appreciable amounts of COX-1 and COX-2 immunostaining were detected throughout the whole wall of arteries of NT and EH. However, different expression patterns of COX-1 and COX-2 were noted when comparing NT with EH. Indeed, in EH vessels, both COX-1 and COX-2 endothelial expression decreased, while a concomitant increase in COX-2 immunostaining was found in the smooth muscle cells. The overall image analysis showed similar percentage levels of COX-1 expression in both NT and EH groups, whereas a predominance of percent COX-2 expression was estimated in EH vessels ( Figure 6 ).
Discussion
The results from this study extend to small arteries from subcutaneous fat previous observations that the endothelial dysfunction, known to characterize EH, depends on an increased intravascular ROS generation, 8, 15, 16 which reduces NO availability. 8, 16 In small vessels from EH, the blunted vascular response to ACh was significantly improved by a selective COX-2 inhibitor, which also partly restored the inhibitory effect of L-NAME on ACh. In addition, an augmented COX-2 protein expression in vessels from these patients was documented. Furthermore, immunohistochemistry indicated a marked upregulation of COX-2 mainly in the vascular media layer. These data provide the first evidence that, in small arteries isolated from EH, an overexpression and increased activity of COX-2 occur, playing a major role in reducing NO availability.
A possible cross-talk between COX and NO was previously investigated. In line with animal data, 1 human studies demonstrated that intra-arterial infusion of indomethacin or acetylsalicylic acid reversed endothelial dysfunction [6] [7] [8] 17 and restored NO availability in the forearm resistance arteries of EH. 7, 8 Similarly, acute infusion of acetylsalicylic acid improved endothelial dysfunction in the forearm microcirculation of hypercholesterolemic patients 18 or in lower extremity resistance arteries of patients with atherosclerosis. 19 Of note, all these results were obtained with nonselective COX inhibitors. Therefore, while highlighting an active detrimental role of COX on NO-derived endothelium-dependent relaxation, these pioneering investigations have left undetermined the question of which COX isoform was effectively involved. Our present results allow to conclude that COX-2 is the key isoenzyme determining a reduction of NO activity in small vessels from EH. Notably, our proposal is in line with results by Widlansky et al 20 showing that administration of the COX-2 inhibitor celecoxib reversed endothelial dysfunction in the brachial artery of EH. Similarly, celecoxib improved the brachial artery flowmediated dilation in patients with coronary artery disease. 21 In essential hypertension or advancing age, the nonselective COX inhibitor indomethacin restored the availability of NO to a similar extent to that obtained with the antioxidant compound ascorbic acid. 7, 8, 16, 22 Furthermore, when indomethacin and ascorbic acid were coinfused, no further amelioration was observed, 8 thus suggesting that ROS production might be the main COX-dependent mechanism responsible for reduced NO availability. Such possibility has been confirmed in this study, documented by a dramatic increase in superoxide production in small vessels from EH, which was reduced by the selective COX-2 inhibitor. Thus, our findings provide the first demonstration that COX-2 is the isoform that actively contributes to intravascular superoxide generation in essential hypertension, whereas COX-1 does not seem to be involved. A support to this view comes from both experimental data, identifying COX-2 as a major intravascular source of ROS production, 23, 24 and clinical data, indicating that COX-2 inhibition by celecoxib reduces the plasma concentrations of ox-low-density lipoprotein, a marker of lipid peroxidation. 21 Our functional experiments also evidenced that the TP receptor blockade failed to improve the ACh-evoked endothelial response, thus excluding the possibility that the contribution of COX-2 to endothelial dysfunction in this clinical setting might involve the production of contracting prostanoids acting on TP receptors.
The remarkable, but incomplete, reduction of ROS excess by COX-2 inhibition raises the question of whether other sources of ROS, differing from COX-2, might concur to promote ROS generation. To this aim, we investigated the possible role of other recognized vascular enzymatic sources of ROS, 3 such as NAD(P)H oxidase, uncoupled NOS, and XO, by selective pharmacological tools. Apocynin and DPI, but not sepiapterin or allopurinol, partly improved NO availability. Consistently, dihydroethidium staining showed that the NAD(P)H oxidase inhibitors (but not sepiapterin or allopurinol) moderately, but significantly, reduced superoxide generation. These findings allow to propose that, in addition to COX-2 that represents the major ROS source, NAD(P)H oxidase also seems to play a role, albeit minor, in ROS generation in this vascular district of EH. These 2 enzymatic pathways might play a synergistic effect in promoting ROS production, as supported by our functional experiments, showing that, when simultaneously infused, DuP-697 and apocynin normalized the inhibitory effect of L-NAME.
Of note, in addition to being an NAD(P)H oxidase inhibitor, DPI has shown to be a NOS inhibitor, 25 an effect that is clearly not emerged in our experiments. We cannot exclude that, in other experimental conditions, the DPI-mediated NOS blockade might be prevalent.
Notably, the lack of effect of COX-2 pathway in small vessels from normotensive controls agrees with the results from Verma et al, 26 who observed that the pharmacological COX-2 blockade does not affect the endothelial function in healthy volunteers. These data strengthen the concept that COX-2 plays a role in endothelial dysfunction specifically in the pathophysiology of essential hypertension or advancing age, as previously suggested. 2, 22 Apparently, at variance with results from this study, previous clinical trials raised concerns about an increased cardiovascular risk associated with the COX-2 inhibitor rofecoxib in patients with rheumatoid arthritis or colorectal adenoma. 27, 28 Furthermore, subsequent studies conducted with more selective COX-2 inhibitors, while not confirming such scientific alert, failed to show any cardiovascular protection by coxibs. 29 However, it is important to point out that our experiments were conducted in acute conditions, in EH characterized by endothelial dysfunction, exposed to low risk of cardiovascular disease, and free of atherosclerotic disease.
In conclusion, in small resistance arteries of EH, COX-2 is overexpressed and functionally active, determining the endothelial dysfunction through a reduction of NO availability. COX-2 represents a major source of ROS generation in essential hypertension. In this context, NAD(P)H oxidase also participates, although with a minor role, in promoting superoxide generation in these patients.
Perspectives
The reduced NO availability is greatly implicated in the pathogenesis of atherosclerotic disease and cardiovascular events. 5 Therefore, this detrimental action of COX-2 on NO availability represents 1 mechanism, whereby COX-2 may promote atherosclerosis, as documented in animal and human models of vascular disease. 30 Our findings also suggest that the COX-2-mediated pathway might be a possible adjunctive therapeutic target to reverse endothelial dysfunction and, hopefully, to prevent cardiovascular disease in EH.
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What Is New?
• This article identifies, among several enzymatic pathways investigated, cyclooxygenase-2 as the major vascular source of oxidative stress generation accounting for endothelial dysfunction in small vessels from essential hypertensive patients.
• Our findings might contribute to improve our knowledge on the complex relationship among endothelial dysfunction, oxidative stress generation, and essential hypertension in humans.
What Is Relevant?
• We identify for the first time a detrimental action of cyclooxygenase-2 on nitric oxide activity in peripheral small vessels from essential hypertensive patients.
• When considering the importance of endothelial dysfunction as a contributor to the progression of atherosclerotic and cardiovascular events, the cyclooxygenase-2-mediated pathway might be a possible adjunctive therapeutic target in essential hypertensive patients.
Summary
In small resistance arteries, isolated from the subcutaneous adipose tissue of essential hypertensive patients, cyclooxygenase-2 is overexpressed and functionally active, inducing endothelial dysfunction by promoting reactive oxygen species generation which in turn reduces the nitric oxide availability. In this context, nicotinamide adenine dinucleotide phosphate oxidase also participates, although with a minor role, in promoting reactive oxygen species generation in these patients.
Supplemental Methods
Study population.
Essential hypertensive patients were recruited among consecutive patients, referred to the Department of Clinical and Experimental Medicine of the University of Pisa, who underwent laparoscopic surgery for cholecystectomy caused by gallbladder stones or adrenalectomy for a benign and non-functioning adrenal mass over 3.5 cm in size. Normotensive subjects were recruited among patients hospitalized into the Department of Surgery, University of Pisa, to undergo laparoscopic surgery for cholecystectomy. The major inclusion criterion was a clinic blood pressure value (after 10 minutes of rest) >140/90 mmHg, confirmed on 2 separate occasions within 1 month, according to current European Guidelines. Secondary forms of hypertension were excluded by routine diagnostic procedures, including morphological and hormonal investigations when adrenal mass was detected. Other exclusion criteria included clinical or biochemical evidence of thyroid dysfunction, ethanol consumption (more than 60 g per day), dyslipidemia, diabetes mellitus, smoking, body mass index >30 kg/m 2 , renal or liver impairment, and established cardiovascular disease. Patients were never treated for hypertension (n=5) or they had not received any medication for at least 1 month before enrollment in the study (n=9). All women recruited in our population were in postmenopausal status, and no one was receiving hormone replacement therapy.
Preparation, Mounting and Measurements in Small Arteries
Small arteries (150 to 300 µm) were isolated from subcutaneous tissue immediately after biopsy sample procurement and mounted on a pressurized myograph. Vessel segments ( 2 mm long) were mounted onto 2 glass cannulas, one of which was positioned until the vessel walls were parallel, and equilibrated in physiologic salt solution (mmol/L: NaCl 120, NaHCO 3 25, KCl 4.7, KH 2 PO 4 1.18, MgSO 4 1.18, CaCl 2 2.5, EDTA 0.026, and glucose 5.5) bubbled continuously with 95% air and 5% CO 2 to achieve pH 7.4 at 37°C. Vessels were pressurized at 60 mm Hg. All functional experiments were performed by measuring dilatory responses to agonists in vessels precontracted with norepinephrine (NE, 10 -6 mol/L). The dose of 1 µM NE was chosen after preliminary experiments of concentration-response curves to NE (from 1 nM to 100 µM) in vessels from normotensive subjects and hypertensive patients. Vessels from the two groups showed concentrations-dependent contractions to the first four concentrations of NE (from 1 nM to 1 µM), resulting in 50-60% of vessel contraction at the dose of 1 µM, similarly in healthy condition or hypertensive disease. Detection of vascular superoxide anion generation. The in situ production of superoxide anion was measured by means of the fluorescent dye dihydroethidium (DHE; Sigma). Three slides per segment were analyzed simultaneously after incubation with antagonists or Krebs solution at 37°C for 30 min. Krebs-HEPES buffer containing 2 μM DHE was then applied onto each section and evaluated under fluorescence microscopy. The percentage of arterial wall area stained with the red signal was evaluated using an imaging software (McBiophotonics Image J; National Institutes of Health, Bethesda, MD). Western Blot analysis of COX-1 and COX-2. Specimens of mesenteric arteries were homogenized in radioimmunoprecipitation assay buffer with a polytron homogenizer and centrifuged at 20,000 rpm for 15 min at 4°C. The resulting supernatants were separated from pellets and stored at -20°C. Aliquots of 50 μg of protein were separated by electrophoresis on 8% sodium dodecylsulfatepolyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane. The blots were then blocked for 1 h with 5% not fat dried milk in Tween-20 tris-buffered saline (TBS-T) and incubated overnight at room temperature with a primary antibody raised against COX-1, COX-2 (Cayman Chemical Co, Ann Arbor, MI, USA) or ß-actin (Sigma-Aldrich, Milano, Italy). After repeated washings with TBS-T, a peroxidase-conjugated secondary antibody was added for 1 h at room temperature. Then, blots were washed and immunoreactive bands were visualized by incubation with chemiluminescent reagents (Immobilon, Millipore, MA, USA) and exposed to Figure S4. Representative western blot of proteins in human small arteries with antibodies against cyclooxygenases. The blot was cut in two parts: the upper part was first hybridized with anti-COX-1 antibody and, after development, was stripped and probed with anti-COX-2 antibody; the lower part was probed for ß-actin and developed.
